Description:

North Central Cancer Treatment Group Arms A and D Only Recurrent Research Tissue Submission Form NCT00079274 Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=8BC1F4CF-E66A-E266-E040-BB89AD436B4E

Link:

https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=8BC1F4CF-E66A-E266-E040-BB89AD436B4E

Keywords:
Versions (4) ▾
  1. 8/27/12
  2. 1/9/15
  3. 6/8/15
  4. 9/20/21
Uploaded on:

September 20, 2021

DOI:
No DOI assigned. To request one please log in.
License:
Creative Commons BY-NC 3.0 Legacy
Model comments:

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for:

Item comments for:

In order to download data models you must be logged in. Please log in or register for free.

North Central Cancer Treatment Group Arms A & D Only Recurrent Research Tissue Submission Form NCT00079274

INSTRUCTIONS: Required for all Arm A and D patients having had a surgical resection for recurrent disease per Addendum 12. Submit this form <= 30 days following surgical resection following disease progression or <= 30 days following activation of Addendum 12 (dependent on IRB approval) if patient has already had disease recurrence and surgical resection to:

Header module
Visit
Instructions
Patient's re-consent given for recurrent tissue specimen use for research on the patient's cancer? (per Addendum 12)
Was sample obtained (check one)
Reason (If no check one)

Similar models